Articles from Massive Bio

During the ongoing government shutdown, ClinicalTrials.gov, the nation’s central registry for medical research and clinical studies, has gone offline, leaving millions of patients with cancer and other serious diseases unable to search for potentially life-saving clinical trials.

Massive Bio, a leader in AI-powered oncology clinical trial matching, today announced the launch of its new key feature on the Patient Connect app. This integration will empower both patients and healthcare providers by simplifying the process of accessing and utilizing electronic health records (EHRs) for advanced cancer care and clinical trial enrollment.

Massive Bio, a leader in AI-enabled oncology trial matching and patient access, and Prognos Health, a provider of actionable lab data, today announced an exclusive, strategic partnership. The collaboration is designed to provide pharmaceutical clients with enhanced, actionable real-world data and insights by combining Massive Bio's deep clinical expertise and network with Prognos Health's robust data harmonization and enrichment framework. This partnership focuses on advancing the patient journey and supporting Massive Bio's mission for oncology patient access and Prognos' mission to unlock the power of data to improve health, particularly in complex clinical populations, including oncology.

In direct support of the White House and CMS’s bold initiative to “Make Health Tech Great Again,” Massive Bio, leader in AI-enabled oncology trial matching, announced its full alignment with the CMS Health Tech Ecosystem and reaffirmed its mission to modernize clinical trial access through secure, AI-powered patient-facing technology. With its Patient Connect app and intelligent assistant DrArturoAI already live and serving patients, Massive Bio stands as one of the first organizations actively delivering on CMS’s interoperability framework at scale.

Massive Bio, a leader in AI-powered oncology patient recruitment and clinical trial matching, has been named in two pivotal categories on CB Insights’ latest AI Drug Research & Development Market Map. This recognition underscores Massive Bio’s innovative contributions to revolutionizing cancer care through advanced artificial intelligence solutions.

Massive Bio, a global company specializing in AI-powered clinical trial matching and oncology data solutions, is participating in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 at McCormick Place in Chicago, Illinois. The company is exhibiting at Booth IH04 in the Innovation Hub, where its team is presenting its technology platform and initiatives to support clinical trial enrollment and data-driven decision-making in oncology.

Massive Bio holds certification from the French Data Protection Authority (CNIL), confirming its compliance with the General Data Protection Regulation (GDPR) and French data privacy laws. This approval allows Massive Bio to securely process patient medical records (MRs) in France via its cloud-based platforms.

A sweeping shift in federal policy—capped, at least temporarily, by a federal judge’s decision to halt the NIH’s proposed 15% indirect cost rate—has brought unprecedented turmoil to the biomedical research community. Despite this legal reprieve for 22 states, experts say the structural impact on research costs, staffing, and operational models could be long-lasting. Today, Massive Bio reaffirms its steadfast commitment to bridging gaps in cancer research and ensuring every patient has equal access to cutting-edge clinical trials.

Massive Bio today proudly announces its inclusion in the White House Office of Science & Technology Policy’s upcoming Cancer Moonshot Fact Sheet, underscoring the company’s groundbreaking efforts to transform clinical trial access and accelerate just-in-time, decentralized trials for cancer patients worldwide. Aligned with its debut at the 2025 JPMorgan Healthcare Conference (JPM 2025), Massive Bio’s $15 million initial investment will fuel its advanced AI-driven clinical trial matching platform, first-of-their-kind pre-screening hubs, and patient-centric ‘hub and spoke’ end-to-end activation model—enabling more than 50,000 unique cancer patients annually and scaling to 250,000 patients globally by 2027.

Massive Bio, a global leader in artificial intelligence (AI) for cancer clinical trial enrollment, has announced the launch of Patient Connect, an innovative and free portal designed to help cancer patients navigate their clinical trial journey across the globe.

Massive Bio, a cutting-edge AI driven clinical trial matching platform provider, and Foundation Medicine, Inc. today announced a strategic collaboration to increase patient access to cutting edge clinical trials. This collaboration unites Massive Bio’s patient matching technology and last-mile solutions with Foundation Medicine’s global expertise and leadership in next generation sequencing (NGS) and network of healthcare providers.

ASCO Annual Meeting– Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a new standard for cancer patient care. This strategic collaboration leverages Inocras's expertise in whole genome sequencing (WGS) and bioinformatics alongside Massive Bio's advanced AI technology for clinical trial matching, with the shared mission of enhancing personalized care for cancer patients.

ASCO Annual Meeting – Massive Bio, renowned leader in AI-driven oncology solutions, and Un Ensayo Para Mi (UEPM), a premier clinical trial search platform in Latin America, are excited to announce an expanded partnership. This collaboration will extend Massive Bio’s reach across nine LATAM countries, including Mexico, Colombia, Brazil, and Argentina, to improve clinical trial access and patient care.

ASCO Annual Meeting – Massive Bio, a renowned leader in AI-driven oncology solutions and Mika Health, the premier oncology digital therapeutic platform, today announced a partnership to significantly expand patient access to psycho oncology services, next-generation sequencing (NGS) biomarker testing, and clinical trials. This collaboration will expand free patient access to Mika’s Digital Therapeutic to treat oncology specific fatigue, anxiety and depression as well as accelerate early access to the right on-market or investigative treatment and appropriate testing at the right time through Massive Bio’s platform.

ASCO Annual Meeting – Massive Bio, pioneering leader in AI-driven oncology solutions, is excited to announce the launch of its latest product, Drug Utilization Optimizer (DUO), at the upcoming ASCO Annual Meeting 2024. The innovative analytics and real-time notification platform is designed to revolutionize how pharmaceutical commercial teams target and engage with physicians, providing unparalleled insights and efficiency.

ASCO Annual Meeting – The Precision Cancer Consortium (PCC), in partnership with Massive Bio, has unveiled compelling results from a comprehensive study conducted on a multi-sponsor pharmaceutical platform. This study rigorously tested Massive Bio's existing artificial intelligence (AI) system, designed to refine the clinical trial matching process using real-world clinical and genomic data, focused on a multi-study oncology platform. The consortium includes top pharmaceutical giants such as AstraZeneca, Bayer, Eli Lilly & Company, GSK, Johnson & Johnson, Novartis, and Roche.

At the forefront of oncological/hematological innovation, Massive Bio, Inc. is set to showcase its pioneering AI technology at the ASCO Annual Meeting 2024, highlighting a major leap in patient and physician engagement in cancer care. The company will unveil its latest advancements in the Massive Bio Deep Learning Clinical Trial Matching System (DLCTMS, aka Synergy-AI), an AI platform designed to transform how cancer clinical trials are accessed and managed globally by structuring vast oncological/hematological data and personalizing patient trial matches in real time.

Trialbee, your global patient recruitment and enrollment solution, today announced its Omnichannel Network partnership with Massive Bio, a global leader in AI enabled patient journey mapping platform, to help better connect cancer patients and their oncologists/hematologists to clinical trials.

Further Group, a leading global provider of turnkey serious illness solutions for the insurance industry with the objective of breaking down barriers to access cutting-edge medical treatments, is delighted to announce a new partnership with Massive Bio, a pioneer in leveraging artificial intelligence to enhance clinical trial matching for cancer patients.

Massive Bio and Asklepieia will utilize their innovative technologies to provide oncologists and patients unparalleled access to crucial clinical trials, personalized cancer treatments, and reports on adequate therapies. Plans are underway for future collaborations with BeStrong and Open Health Alliance.

Massive Bio, an AI-powered platform connecting patients with clinical trials and CureMatch, a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision medicine support for oncology, and have announced a transformative partnership aimed at revolutionizing cancer treatment through advanced genomics, artificial intelligence, and expansive clinical trial accessibility.

Massive Bio, a globally recognized leader in the oncology space, has proudly announced its appointment as a founding member of CancerX, a groundbreaking initiative endorsed by The White House. This appointment situates Massive Bio at the forefront of a national public-private partnership aiming to revolutionize the fight against cancer. Spearheaded by the rejuvenated Cancer Moonshot initiative, CancerX is co-hosted by Moffitt Cancer Center and Digital Medicine Society (DiMe), bringing together diverse stakeholders to foster greater equity and reduce financial toxicity in cancer care and research.

Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care. This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network.

Massive Bio, a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC), a collaboration of several global biopharmaceutical companies, to optimize clinical trial matching through their innovative AI analytics tools. PCC was established in 2022 with a shared vision of enabling access to comprehensive testing for all cancer patients globally, and is currently comprised of AstraZeneca, Bayer, Eli Lilly & Company, GSK, Johnson & Johnson/Janssen, Novartis, and Roche. The partnership will incorporate PCC member clinical trial protocols and patient inclusion and exclusion criteria into existing machine learning matching algorithms in SYNERGY-AI leveraged within Massive Bio’s Deep Learning Clinical Trial Matching System (DLCTMS). This will optimize the quality and efficiency of matching patients to trials across sponsor programs and improve patient access to targeted Next Generation Sequencing (NGS) testing and tailored interventions.

Massive Bio, a world-renowned provider of personalized oncology solutions, is set to showcase its groundbreaking GPT4 AI chatbots - AskFiona AI and DrArturo AI at ASCO 2023. These innovative, AI-driven solutions will redefine cancer care, establishing new paradigms in patient and provider engagement and global oncological research.

Massive Bio, which uses artificial intelligence and concierge service to match cancer patients to oncology clinical trials regardless of their location or financial circumstances, continues its expansion beyond the United States. The company now operates on three continents and in 12 countries, with a particularly strong presence in the European Union (EU). *After passage of new pharmaceutical legislation known as the Clinical Trials Regulation, which entered into application on January 31, 2022, the EU offers an attractive and favorable environment for carrying out clinical research on a large scale, with high standards of public transparency and safety for clinical trial participants. Thus, Massive Bio aims to be the first global oncology patient recruitment company to establish a material footprint in the EU. Massive Bio supports 1,750 clinical sites (650 of these sites are outside United States) and has partnerships with 21 pharmaceutical companies and five clinical research organizations globally.

Cancer is an unfortunate reality that has touched many of us at some point. If you or a loved one has cancer, you may have heard or read that clinical trials can provide access to innovative treatments. But what exactly is a clinical trial? In a video titled “Massive Bio Explains: What Are Clinical Trials?” company Co-Founder and Chief Medical Officer Arturo Loaiza-Bonilla, MD, describes how clinical trials work, what to expect if you enroll in one, and why clinical trials can be an essential treatment option for many cancer patients.

Massive Bio, a leader in the use of artificial intelligence (AI) to match cancer patients to clinical trials, is honored to announce that it has been named to the New York Digital Health 100 (DH100) for the second consecutive year. The DH100, which is published annually by Digital Health New York (DHNY), showcases the most exciting and innovative health start-ups in the New York region and is featured in the New York Healthcare Innovation Report 2023. Published for the sixth time this year, the report is an in-depth look at the leaders, trends, and data that are shaping healthcare innovation in New York. DHNY’s stated goal is to “create a connected community that shares ideas, leads in new directions, and builds success for the entire healthcare ecosystem.”

Massive Bio, a leader in AI-powered cancer treatment, today announced plans to launch a new AI-powered drug matching product in 2023 that will enable oncologists to proactively identify more cancer treatment options for their patients, including recently approved drugs as well as active clinical trials. The new drug matching product will also help biotech and pharmaceutical companies better target which patients and physicians need the latest drugs, improving their go-to-market efficiency. Massive Bio plans to launch its first drug matching product in first half 2023 and will deliver general availability later this year.

Massive Bio, a leader in AI-powered cancer clinical trial enrollment, today announced the addition of two executives to its C-suite. Verily veteran Özgür “Oz” Huner joins as Massive Bio’s first Chief Product Officer, and Erkan Terzi has been promoted to Chief Marketing Officer. Both executives will report to CEO and co-founder Selin Kurnaz and work alongside co-founders Chief Medical Officer Arturo Loaiza-Bonilla and Chief Technology Officer and Chief Operating Officer Cagatay Culcuoglu in leading and driving Massive Bio’s product and growth strategy.

Massive Bio, a leader in AI-powered cancer clinical trial enrollment, announced a strategic partnership with Azra AI, a healthcare technology company that uses proprietary AI software to identify cancer diagnoses in real time and accelerate the patient care process. Combined with Massive Bio’s ability to surface personalized clinical trial options for patients, the two companies working together provide early identification and precise treatment options, further improving cancer clinical care.

Massive Bio, a leader in AI-powered cancer clinical trial enrollment, today announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022 – nine months sooner than expected. The Massive Bio platform matches cancer patients with relevant clinical trials using artificial intelligence (AI), empowering patients to find treatment options faster – while enabling life sciences companies to conduct broader, more inclusive population-based recruitment rather than traditional site-specific recruitment.

Massive Bio has been named a Best in Class Quarterfinalist in the UCSF | Health Hub: Digital Health Awards competition. These prestigious awards are granted annually by UCSF Health Hub (a non-profit organization affiliated with the University of California San Francisco) to recognize “the achievements of innovative health tech companies that are dramatically improving healthcare through the use of technology in the digital health industry.”

Massive Bio, a leader in AI-powered cancer clinical trial enrollment, announced a strategic partnership with Perthera.ai, a pioneer in connecting oncologists and patients with biomarker-based therapy options. Perthera.ai’s patented ranked therapy recommendations complement Massive Bio’s screening and analysis to empower more cancer patients to find an appropriate clinical trial.

Massive Bio, which uses its proprietary artificial intelligence-based platform to match cancer patients to clinical trials regardless of where they live or their financial circumstances, is expanding its operations in Europe. With support from Series B investments received in the first half of this year, Massive Bio announced the hiring of three new team members who will help expand the company's global operations, intensify its marketing activities, develop new data sets and products, and expand its M&A efforts. The new recruits are Toygun Onaran, who will serve as Head of Strategy; Mert Sarı, who will be Regional Manager; and Sinan Fındık, who comes on board as Clinical Research and Data Manager.

Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric clinical trial enrollment for oncology, and AdhereTech, a pioneer and leading provider of smart devices that connect patients to care with real-time interventions, announced their partnership to provide advanced, data-driven digital health technology solutions, focusing in oral oncolytic agents providing real-time integrated access to care for cancer patients to precision oncology drugs and leading-edge clinical trials. Both companies were recognized in the 2022 NYC Digital Health 100 which showcases the most exciting digital health companies in the New York region.